Draft guidance consultation You can now review and comment on this draft guideline. The consultation closes on Tuesday 08 July 2025 at 5pm. In line with NICE’s commitment to incorporate technology ...

The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

What this means in practice Obe‑cel is not required to be funded in the NHS in England to treat relapsed or refractory B‑cell precursor acute lymphoblastic leukaemia in adults. It should not be used ...

NICE news for life sciences Every 2 months Our latest news and updates for those working within the life sciences sector. Subscribe for information on: our work to improve patient access to innovative ...

Notice of Appeal Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949] NICE has received 1 appeal, that falls within one or more of the two strictly ...

This means the medicines should not be provided on the NHS as they are not good value for money. Last month the appraisal committee met to consider new information submitted as part of its additional ...

Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults. Last reviewed: 19 June 2025 Next review: This guidance will be ...

NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its ...

Evaluation committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered as a streamlined evaluation by the lead team of committee D, ...

Capacity impact The capacity impact of this topic will have been realised while the treatment has been in the Cancer Drugs Fund. So, no significant change in capacity is anticipated. Localities can ...

Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers. Last reviewed: 19 June 2025 Guidance development process LSA guidance evaluates categories of ...